FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

FibroBiologics (Nasdaq:FBLG) announced that its Founder and CEO Pete O'Heeron and CSO Hamid Khoja, Ph.D., will join a fireside chat at the H.C.

Rhea-AI Summary

FibroBiologics (Nasdaq:FBLG) announced that its Founder and CEO Pete O'Heeron and CSO Hamid Khoja, Ph.D., will join a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, held June 30–July 1, 2026.

The session is scheduled for 1:00 p.m. ET on June 30, 2026 and will be moderated by Matthew Caufield, Senior Research Healthcare Analyst at H.C. Wainwright & Co. FibroBiologics will also be available for one-on-one investor meetings during the event.

Argus Jun 30 session

+19.22% close to close Open Argus

Details

News Market Reaction – FBLG

On Jun 30, the day this news came out, FBLG closed 19.22% above the previous close.

Data tracked by StockTitan Argus for the Jun 30 session.

Key Figures

Intellectual property: 270+ patents issued and pending Conference edition: 4th Annual Conference dates: June 30 – July 1, 2026 +1 more

Intellectual property

270+ patents issued and pending

Company patent portfolio referenced in conference announcement

Conference edition

4th Annual

H.C. Wainwright Cell Therapy Virtual Conference

Conference dates

June 30 – July 1, 2026

H.C. Wainwright Cell Therapy Virtual Conference schedule

Fireside chat time

1:00 p.m. ET on June 30, 2026

Scheduled FibroBiologics fireside chat slot

Historical Context

5 past events · Latest: Jun 26

5 events

1. Jun 26

   Private placement

   24h Move

   +12.7%

   Dilutive private placement at $0.735 with additional warrant financing potential.

2. Jun 22

   Patent allowance

   24h Move

   +0.1%

   USPTO Notice of Allowance for topical fibroblast spheroid wound-healing patent.

3. Jun 16

   Clinical progress

   24h Move

   -9.3%

   Update on first patient dosing and additional GMP manufacturing for CYWC628 trial.

4. Jun 03

   Clinical trial start

   24h Move

   +1.9%

   First patients dosed in Phase 1/2 CYWC628 trial for diabetic foot ulcers.

5. May 22

   Preclinical data

   24h Move

   +0.0%

   Preclinical psoriasis data for CYPS317 presented at dermatology conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

clinical-stage, fibroblasts, fibroblast-derived materials, cell therapy

4 terms

clinical-stage medical

"FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

fibroblasts medical

"focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials"

Fibroblasts are common cells in connective tissue that manufacture the structural proteins and fibers—like collagen—that form and repair the body's scaffolding, helping wounds heal and tissues hold their shape. For investors, fibroblasts matter because they are frequent targets or tools in drug development, regenerative medicine and safety testing: changes in their behavior can signal whether a therapy will work, cause side effects or enable new medical products, much like a construction crew determines the strength and finish of a building.

fibroblast-derived materials medical

"potential cures for chronic diseases using fibroblasts and fibroblast-derived materials"

Materials produced or conditioned by fibroblasts—common connective‑tissue cells that secrete the structural proteins and other components tissues use as a scaffold. Investors should care because these biologically sourced materials are used in wound care, tissue engineering, cosmetic and regenerative products; their quality, scalability and regulatory path affect a product’s performance, manufacturing cost and commercial potential, much like the quality of bricks and mortar determines a building’s durability.

cell therapy medical

"H.C. Wainwright 4th Annual Cell Therapy Virtual Conference taking place June 30 – July 1, 2026"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, and Chief Scientific Officer, Hamid Khoja, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference taking place June 30 – July 1, 2026.

The fireside chat is scheduled for 1:00 p.m. ET on June 30, 2026, and will be moderated by Matthew Caufield, Senior Research Healthcare Analyst at H.C. Wainwright & Co. FibroBiologics will be available for one-on-one meetings throughout the event.

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.  

About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-to-participate-in-fireside-chat-at-hc-wainwright-4th-annual-cell-therapy-virtual-conference-302813774.html

SOURCE FibroBiologics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FibroBiologics (Nasdaq:FBLG) announce for June 30, 2026?

FibroBiologics announced leadership participation in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. According to FibroBiologics, the event runs June 30–July 1, 2026 and includes one-on-one meeting availability.

When is FibroBiologics' fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference?

FibroBiologics' fireside chat is scheduled for 1:00 p.m. ET on June 30, 2026. According to FibroBiologics, this session is part of the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

Who will represent FibroBiologics (FBLG) at the H.C. Wainwright Cell Therapy Conference?

FibroBiologics will be represented by Founder and CEO Pete O'Heeron and Chief Scientific Officer Hamid Khoja, Ph.D. According to FibroBiologics, they will participate in a moderated fireside chat during the virtual conference.

Will FibroBiologics (FBLG) hold one-on-one investor meetings at the 2026 H.C. Wainwright Cell Therapy Conference?

FibroBiologics plans to be available for one-on-one meetings throughout the virtual event. According to FibroBiologics, investors and other stakeholders can arrange meetings during the June 30–July 1, 2026 conference dates.

How can investors get more information about FibroBiologics' participation in the H.C. Wainwright Cell Therapy Conference?

Investors can visit FibroBiologics' website or email info@fibrobiologics.com for details. According to FibroBiologics, updates are also shared via its LinkedIn, YouTube, Facebook and X social media channels.